2-[4-(2,3-dihydro-1H-inden-1-yl)piperazin-1-yl]ethanamine | 187221-94-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2-[4-(2,3-dihydro-1H-inden-1-yl)piperazin-1-yl]ethanamine
• CAS: 187221-94-9
• 化学式: C₁₅H₂₃N₃
• 分子量: 245.368
• InChiKey: YABLKWFIOOTQGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,4,5-三甲氧基苯甲酰氯 、 2-[4-(2,3-dihydro-1H-inden-1-yl)piperazin-1-yl]ethanamine 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 4.0h， 以72%的产率得到N-[2-[4-(2,3-dihydro-1H-inden-1-yl)piperazin-1-yl]ethyl]-3,4,5-trimethoxybenzamide
  参考文献：
  名称：

  New Benzocycloalkylpiperazines, Potent and Selective 5-HT_1A Receptor Ligands

  摘要：

  A series of 1-(benzocycloalkyl)-4-(benzamidoalkyl)piperazine derivatives was prepared in order to obtain compounds with a high affinity and selectivity for 5-HT1A receptors. The modifications of aromatic substituents, the length of the alkyl chain, and the size of the ring were explored. Most of N-(1,2,3,4-tetrahydronaphthyl)-N'-(benzamidoethyl)piperazines (32-37) were bound to 5-HT1A receptors in a nanomolar range and presented a high degree of selectivity. After resolution, levorotatory enantiomers showed affinity and selectivity higher than those of dextrorotatory ones for 5-HT1A sites. The agonist type activity of selected derivatives was also confirmed in vitro on the inhibition of the activation of adenylate cyclase induced by forskolin and, in vivo, on the induction of the lower lip retraction in rats.

  DOI：

  10.1021/jm950759z
• 作为产物：
  描述：

  2,3-二氢-1H-茚-1-醇 在 氢氧化钾 、 氯化亚砜 、 potassium carbonate 、 一水合肼 、 sodium iodide 作用下， 以 甲醇 、 甲苯 、 乙腈 为溶剂， 反应 49.0h， 生成 2-[4-(2,3-dihydro-1H-inden-1-yl)piperazin-1-yl]ethanamine
  参考文献：
  名称：

  New Benzocycloalkylpiperazines, Potent and Selective 5-HT_1A Receptor Ligands

  摘要：

  A series of 1-(benzocycloalkyl)-4-(benzamidoalkyl)piperazine derivatives was prepared in order to obtain compounds with a high affinity and selectivity for 5-HT1A receptors. The modifications of aromatic substituents, the length of the alkyl chain, and the size of the ring were explored. Most of N-(1,2,3,4-tetrahydronaphthyl)-N'-(benzamidoethyl)piperazines (32-37) were bound to 5-HT1A receptors in a nanomolar range and presented a high degree of selectivity. After resolution, levorotatory enantiomers showed affinity and selectivity higher than those of dextrorotatory ones for 5-HT1A sites. The agonist type activity of selected derivatives was also confirmed in vitro on the inhibition of the activation of adenylate cyclase induced by forskolin and, in vivo, on the induction of the lower lip retraction in rats.

  DOI：

  10.1021/jm950759z

文献信息

• 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases
  申请人：Boettcher Andreas

  公开号：US20100125064A1

  公开（公告）日：2010-05-20

  The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula I, wherein R 1 , R 2 , R 3 , R 4 , R A , Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.

  本发明涉及能够抑制p53或其变体与MDM2和/或MDM4或其变体相互作用的3-杂环基吲哚化合物，其中所述化合物具有式I，其中R1、R2、R3、R4、RA、Y和Y的定义见说明书。由于其活性，这些化合物可用于治疗由MDM2和/或MDM4或其变体介导的各种疾病和疾病，例如炎症性或增殖性疾病或细胞保护。
• 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
  申请人：Novartis AG

  公开号：EP2142535A2

  公开（公告）日：2010-01-13
• US8053457B2
  申请人：——

  公开号：US8053457B2

  公开（公告）日：2011-11-08
• [EN] 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] 3-IMIDAZOLYL-INDOLES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：NOVARTIS AG

  公开号：WO2008119741A2

  公开（公告）日：2008-10-09

  [EN] The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I) wherein R¹, R², R³, R⁴, R^A, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.
  [FR] L'invention porte sur des composés 3-hétérocyclyl indolylés, capables d'inhiber l'interaction entre p53, ou des variantes de celui-ci, et MDM2 et/ou MDM4, ou des variantes de ceux-ci, respectivement, lesdits composés ayant la formule (I) dans laquelle R¹, R², R³, R⁴, R^A, Y et Y sont tels que définis dans la description. En raison de leur activité, les composés sont utiles dans le traitement de divers troubles et diverses maladies à médiation par l'activité de MDM2 et/ou MDM4, ou des variantes de ceux-ci, tels que des maladies inflammatoires ou prolifératives ou dans la protection de cellules.
• New Benzocycloalkylpiperazines, Potent and Selective 5-HT_1A Receptor Ligands
  作者：Youssef El Ahmad、Elisabeth Laurent、Philippe Maillet、Akram Talab、Jean François Teste、Raymond Dokhan、Gilles Tran、Roland Ollivier

  DOI：10.1021/jm950759z

  日期：1997.3.1

  A series of 1-(benzocycloalkyl)-4-(benzamidoalkyl)piperazine derivatives was prepared in order to obtain compounds with a high affinity and selectivity for 5-HT1A receptors. The modifications of aromatic substituents, the length of the alkyl chain, and the size of the ring were explored. Most of N-(1,2,3,4-tetrahydronaphthyl)-N'-(benzamidoethyl)piperazines (32-37) were bound to 5-HT1A receptors in a nanomolar range and presented a high degree of selectivity. After resolution, levorotatory enantiomers showed affinity and selectivity higher than those of dextrorotatory ones for 5-HT1A sites. The agonist type activity of selected derivatives was also confirmed in vitro on the inhibition of the activation of adenylate cyclase induced by forskolin and, in vivo, on the induction of the lower lip retraction in rats.